According to the Zhitong Finance App, Cansino Biotech (06185.HK) announced its results for the first three quarters of 2026, achieving operating income of 882 million yuan for the nine months ending September 30, 2026, an increase of 27.4%; net profit attributable to shareholders of listed companies was 16.2913 million yuan, an increase of 12.82% over the previous year. Basic earnings per share were $0.07.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.